Myopia progression data identifies key predictors of teenage High Myopia (HM), which may guide timing of early interventions to reduce risk of HM later in life
Higher-order aspheric IOL shown to provide pupil independent performance and better simulated dysphotopsia profile than zonal IOLs in optical bench testing
Johnson & Johnson Vision, a global leader in eye health and part of the Johnson & Johnson Medical Devices Companies, will present nearly thirty posters and papers of research data on myopia, intraocular lens (IOL), phacoemulsification, refractive, and meibomian gland dysfunction at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting.
This year’s premier vision research meeting is being held virtually May 1 – 7, and Johnson & Johnson Vision posters, papers, and presentations can be accessed through the virtual meeting platform hosted by Pathable.
“I’m excited about the data Johnson & Johnson Vision is presenting at ARVO this year,” said Xiao-Yu Song, MD, PhD, Global Head of Research and Development, Johnson & Johnson Vision Care, Inc.
“We’ve identified markers that can guide clinicians in early interventions for myopia patients and are sharing results from our research that compares the optical and simulated clinical performance of a higher-order aspheric IOL with that of two zonal refractive IOLs.”
Myopia Research Evaluating the Association of Early Childhood Rapid Myopic Progression with High Myopia in Teenagers.
Myopia is a chronic and progressive disease that poses the biggest eye health threat of the 21st Century. Young children that are less than 12 years of age and become myopic are the most vulnerable to develop high myopia and are at increased risk of sight-threatening eye diseases later in life.
There is no safe level of myopia. From an early age, frequent eye examinations, measuring and monitoring both refractive error and axial length is highly recommended in all children with even moderate risk of myopia progression.
At ARVO 2021, Johnson & Johnson Vision will present research aiming to better understand how myopia progresses and how it might be intercepted by investigating underlying mechanisms. The results from this and other studies stem from the company’s comprehensive myopia clinical research program, as well as from the research collaboration with the Singapore Eye Research Institute (SERI):
Children (n=1,051) were followed from baseline (6-11 years-old) over a mean follow-up of 6.9±1.0 years. Regression analyses showed myopia progression in early childhood combined with other key factors, such as baseline SE or AL or age of onset of myopia, was a good predictor of teenage HM. The authors suggest clinicians use these factors to guide timing of early interventions to potentially reduce the risk of HM later in life.
The Optical and Simulated Clinical Performance of Higher-Order Aspheric IOL and Standard Zonal IOLs
More than 90% of people develop cataracts—the clouding and yellowing of the lens in the eye—by the age of 65. While part of the normal aging of the eye, left untreated, cataracts cause vision to deteriorate over time.
Cataract surgery is one of the most common outpatient procedures performed and has a success rate of approximately 98%. During the surgery, an IOL is implanted to replace the eye’s natural lens, helping restore vision after a cataract has been removed.
The poster being presented at ARVO 2021 compares the simulated optical performance of a higher-order aspheric IOL with that of two zonal refractive IOLs with a central add power:
Binocular visual acuity was simulated and calculated from measurements collected in an average corneal eye (ACE) model, and computer simulations in a physiological eye were performed to determine the halo profile for different pupil sizes.
The results show that the addition of an add power results in a strong pupil dependence and an optical performance that resembles a standard multifocal IOL, with bifocal defocus curves, loss in distance image quality and the perception of halos.
In comparison, the higher-order aspheric IOL creates a continuous change in power to extend the depth of focus, providing a pupil independent performance, and better simulated dysphotopsia profile than the zonal IOLs.
Additional posters and papers from Johnson & Johnson Vision and its research partners at the ARVO Annual Meeting 2021 include:
Myopia:
Cataract, Refractive, and Meibomian Gland Dysfunction: